Intrahepatic Cholestasis After Liver Transplantation

Clinics in Liver Disease

Volumn 12, Issue 1, 2008, Pages 111-129

  Corbani, A ^a   Burroughs, A K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZATHIOPRINE; CEFOTAXIME; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; IMMUNOGLOBULIN; ITRACONAZOLE; KETOCONAZOLE; TACROLIMUS; TOBRAMYCIN; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ARTERY THROMBOSIS; BACTEREMIA; BACTERIAL INFECTION; BILE DUCT INJURY; BILIRUBIN BLOOD LEVEL; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW TOXICITY; CHOLESTASIS; CHOLESTATIC HEPATITIS; CRYOPRECIPITATE; GRAFT DYSFUNCTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INTRAHEPATIC CHOLESTASIS; KAPOSI SARCOMA; LIVER ISCHEMIA; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; MYCOSIS; NODULAR HYPERPLASIA; RECURRENT DISEASE; REPERFUSION INJURY; REVIEW; SEPSIS; SIDE EFFECT; THROMBOCYTE TRANSFUSION; VIRUS INFECTION;

CHOLESTASIS, INTRAHEPATIC; HUMANS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 38549146497     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.11.001     Document Type: Review

References (109)

1. Fusai G., Dhaliwal P., Rolando N., et al. Incidence and risk factors for the development of prolonged and severe intrahepatic cholestasis after liver transplantation. Liver Transpl 12 (2006) 1626-1633
2. Williams J.W., Vera S., Peters T.G., et al. Cholestatic jaundice after hepatic transplantation: a nonimmunologically mediated event. Am J Surg 151 (1986) 65-70
3. Adler M., Deprez C., Rickaert F., et al. Cholestatic syndrome due to preservation injury after liver transplantation. Transplant Proc 20 (1988) 644-645
4. Clavien P.A. Sinusoidal endothelial cell injury during hepatic preservation and reperfusion. Hepatology 28 (1998) 281-285
5. Tanigawa K. Reperfusion injury in liver transplantation. Curr Opin Anaesthesiol 13 (2000) 349-354
6. Serracino-Inglott F., Habib N.A., and Mathie R.T. Hepatic ischemia-reperfusion injury. Am J Surg 181 (2001) 160-166
7. Cutrin J.C., Cantino D., Biasi F., et al. Reperfusion damage to the bile canaliculi in transplanted human liver. Hepatology 24 (1996) 1053-1057
8. Sanchez-Urdazpal L., Gores G.J., Ward E.M., et al. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology 17 (1993) 605-609
9. Badiee P., Kordbacheh P., Alborzi A., et al. Fungal infections in solid organ recipients. Exp Clin Transplant 3 (2005) 385-389
10. Sterneck M., Wiesner R., Ascher N., et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 14 (1991) 806-810
11. Vierling J.M., and Fennell Jr. R.H. Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. Hepatology 5 (1985) 1076-1082
12. Busuttil R.W., and Klintmalm G.K. Transplantation of the liver. 2nd edition (2005), Elsevier Saunders, Philadelphia
13. Briceno J., Marchal T., Padillo J., et al. Influence of marginal donors on liver preservation injury. Transplantation 74 (2002) 522-526
14. Cho J.Y., Suh K.S., Lee H.W., et al. Hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration after living donor liver transplantation. Transpl Int 19 (2006) 807-813
15. Wiesner R.H., Demetris A.J., Belle S.H., et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28 (1998) 638-645
16. Liu L.U., Bodian C.A., Gondolesi G.E., et al. Marked differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation 80 (2005) 1072-1080
17. Berlakovich G.A., Imhof M., Karner-Hanusch J., et al. The importance of the effect of underlying disease on rejection outcomes following orthotopic liver transplantation. Transplantation 61 (1996) 554-560
18. Datta G.S., Hudson M., Burroughs A.K., et al. Grading of cellular rejection after orthotopic liver transplantation. Hepatology 21 (1995) 46-57
19. Famularo G., De S.C., and Nicotra G.C. Jaundice and the sepsis syndrome: a neglected link. Eur J Intern Med 14 (2003) 269-271
20. Narita R., Murata M., Kihara Y., et al. Sepsis presenting with severe jaundice. Am J Gastroenterol 96 (2001) 3214-3215
21. Gilroy R.K., Mailliard M.E., and Gollan J.L. Gastrointestinal disorders of the critically ill: cholestasis of sepsis. Best Pract Res Clin Gastroenterol 17 (2003) 357-367
22. Sherlock S, Dooley JS. Disease of the liver and biliary system. 11th edition. Oxford: Blackwell Scientific Publications.
23. Chand N., and Sanyal A.J. Sepsis-induced cholestasis. Hepatology 45 (2007) 230-241
24. Wade J.J., Rolando N., Hayllar K., et al. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 21 (1995) 1328-1336
25. Blair J.E., and Kusne S. Bacterial, mycobacterial, and protozoal infections after liver transplantation: part I. Liver Transpl 11 (2005) 1452-1459
26. Grazi G.L., Mazziotti A., Fisichella S., et al. Antimicrobial prophylaxis with ceftriaxone for prevention of early postoperative infections after 49 liver transplantations. J Chemother 12 Suppl 3 (2000) 10-16
27. Davies S.E., Portmann B.C., O'Grady J.G., et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 13 (1991) 150-157
28. Singh N., Wagener M.M., Obman A., et al. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 10 (2004) 844-849
29. McDonald J.W.D., Burroughs A.K., and Feagan B.G. Evidence-based gastroenterology and hepatology. 2nd edition (2004), Blackwell Publishing
30. Mutimer D. CMV infection of transplant recipients. J Hepatol 25 (1996) 259-269
31. Winston D.J., Wirin D., Shaked A., et al. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 346 (1995) 69-74
32. Caplin B., Sweny P., Burroughs A., et al. Antiviral treatment after solid organ transplantation. Lancet 366 (2005) 806-807
33. Singh N., and Wagener M.M. Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 144 (2006) 456-457
34. Patel R., and Paya C.V. Infections in solid-organ transplant recipients. Clin Microbiol Rev 10 (1997) 86-124
35. Cervera C., Marcos M.A., Linares L., et al. A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients. Transplantation 82 (2006) 979-982
36. Humar A., Kumar D., Caliendo A.M., et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 73 (2002) 599-604
37. Singh N. Human herpesviruses-6, -7 and -8 in organ transplant recipients. Clin Microbiol Infect 6 (2000) 453-459
38. Saad R.S., Demetris A.J., Lee R.G., et al. Adenovirus hepatitis in the adult allograft liver. Transplantation 64 (1997) 1483-1485
39. Adam R., Cailliez V., Majno P., et al. Normalised intrinsic mortality risk in liver transplantation: European liver transplant registry study. Lancet 356 (2000) 621-627
40. Cruciani M., Mengoli C., Malena M., et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 12 (2006) 850-858
41. Bradbury B.D., and Jick S.S. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 22 (2002) 697-700
42. Bissell D.M., Gores G.J., Laskin D.L., et al. Drug-induced liver injury: mechanisms and test systems. Hepatology 33 (2001) 1009-1013
43. de Boer N.K., Mulder C.J., and van Bodegraven A.A. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med 63 (2005) 444-446
44. Farrell G.C. Drug-induced liver disease (1994), Churchill Livingstone
45. Ben-Ari Z., Pappo O., and Mor E. Intrahepatic cholestasis after liver transplantation. Liver Transpl 9 (2003) 1005-1018
46. Sanchez-Campos S., Lopez-Acebo R., Gonzalez P., et al. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. Transplantation 66 (1998) 84-88
47. Ganschow R., Albani J., Grabhorn E., et al. Tacrolimus-induced cholestatic syndrome following pediatric liver transplantation and steroid-resistant graft rejection. Pediatr Transplant 10 (2006) 220-224
48. Fisher A., Mor E., Hytiroglou P., et al. FK506 hepatotoxicity in liver allograft recipients. Transplantation 59 (1995) 1631-1632
49. Mainra R.R., and Card S.E. Trimethoprim-sulfamethoxazole-associated hepatotoxicity: part of a hypersensitivity syndrome. Can J Clin Pharmacol 10 (2003) 175-178
50. Findor J.A., Sorda J.A., Igartua E.B., et al. Ketoconazole-induced liver damage. Medicina (B Aires) 58 (1998) 277-281
51. Lake-Bakaar G., Scheuer P.J., and Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 294 (1987) 419-422
52. Adriaenssens B., Roskams T., Steger P., et al. Hepatotoxicity related to itraconazole: report of three cases. Acta Clin Belg 56 (2001) 364-369
53. Girois S.B., Chapuis F., Decullier E., et al. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 24 (2005) 119-130
54. Lo C.M., Fan S.T., Liu C.L., et al. Minimum graft size for successful living donor liver transplantation. Transplantation 68 (1999) 1112-1116
55. Ben-Haim M., Emre S., Fishbein T.M., et al. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. Liver Transpl 7 (2001) 948-953
56. Kawasaki S., Makuuchi M., Matsunami H., et al. Living related liver transplantation in adults. Ann Surg 227 (1998) 269-274
57. Dahm F., Georgiev P., and Clavien P.A. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant 5 (2005) 2605-2610
58. Emond J.C., Renz J.F., Ferrell L.D., et al. Functional analysis of grafts from living donors: implications for the treatment of older recipients. Ann Surg 224 (1996) 544-552
59. Quaglia A.F., Del Vecchio B.G., Greaves R., et al. Development of ductopaenic liver allograft rejection includes a "hepatitic" phase prior to duct loss. J Hepatol 33 (2000) 773-780
60. Devlin J.J., O'Grady J.G., Tan K.C., et al. Ethnic variations in patient and graft survival after liver transplantation: identification of a new risk factor for chronic allograft rejection. Transplantation 56 (1993) 1381-1384
61. Nair S., Eustace J., and Thuluvath P.J. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 359 (2002) 287-293
62. Gunsar F., Rolando N., Pastacaldi S., et al. Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transpl 9 (2003) 605-611
63. Silva M.A., Jambulingam P.S., Gunson B.K., et al. Hepatic artery thrombosis following orthotopic liver transplantation: a 10-year experience from a single centre in the United Kingdom. Liver Transpl 12 (2006) 146-151
64. Washington K. Update on post-liver transplantation infections, malignancies, and surgical complications. Adv Anat Pathol 12 (2005) 221-226
65. Sanchez-Urdazpal L., Batts K.P., Gores G.J., et al. Increased bile duct complications in liver transplantation across the ABO barrier. Ann Surg 218 (1993) 152-158
66. Te H.S., and Baker A.L. Intrahepatic cholestasis following liver transplantation. Clin Liver Dis 3 (1999) 633-649
67. Heneghan M.A., and Sylvestre P.B. Cholestatic diseases of liver transplantation. Semin Gastrointest Dis 12 (2001) 133-147
68. Busquets J., Castellote J., Torras J., et al. Liver transplantation across Rh blood group barriers increases the risk of biliary complications. J Gastrointest Surg 11 (2007) 458-463
69. Burroughs A.K., Sabin C.A., Rolles K., et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 367 (2006) 225-232
70. Qian Y.B., Liu C.L., Lo C.M., et al. Risk factors for biliary complications after liver transplantation. Arch Surg 139 (2004) 1101-1105
71. Jagannath S., and Kalloo A.N. Biliary complications after liver transplantation. Curr Treat Options Gastroenterol 5 (2002) 101-112
72. Tung B.Y., and Kimmey M.B. Biliary complications of orthotopic liver transplantation. Dig Dis 17 (1999) 133-144
73. Shastri Y.M., Hoepffner N.M., Akoglu B., et al. Liver biochemistry profile, significance and endoscopic management of biliary tract complications post orthotopic liver transplantation. World J Gastroenterol 13 (2007) 2819-2825
74. Buis C.I., Verdonk R.C., Van der Jagt E.J., et al. Nonanastomotic biliary strictures after liver transplantation. Part 1: radiological features and risk factors for early vs. late presentation. Liver Transpl 13 (2007) 708-718
75. Margarit C., Hidalgo E., Lazaro J.L., et al. Biliary complications secondary to late hepatic artery thrombosis in adult liver transplant patients. Transpl Int 11 Suppl 1 (1998) S251-S254
76. Nishida S., Nakamura N., Kadono J., et al. Intrahepatic biliary strictures after liver transplantation. J Hepatobiliary Pancreat Surg 13 (2006) 511-516
77. Sanchez-Urdazpal L., Gores G.J., Ward E.M., et al. Clinical outcome of ischemic-type biliary complications after liver transplantation. Transplant Proc 25 (1993) 1107-1109
78. O'Connor H.J., Vickers C.R., Buckels J.A., et al. Role of endoscopic retrograde cholangiopancreatography after orthotopic liver transplantation. Gut 32 (1991) 419-423
79. Kotlyar D.S., Campbell M.S., and Reddy K.R. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol 101 (2006) 1370-1378
80. Neuberger J. Transplantation for primary biliary cirrhosis. Semin Liver Dis 17 (1997) 137-146
81. Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl 9 (2003) 539-546
82. Wu L., Rappaport D.C., Hanbidge A., et al. Lymphoproliferative disorders after liver transplantation: imaging features. Abdom Imaging 26 (2001) 200-206
83. Jacob D.A., Neumann U.P., Bahra M., et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 20 (2006) 211-220
84. Gautam M., Cheruvattath R., and Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 12 (2006) 1813-1824
85. Cholongitas E, Vibhakorn S, Papatheodoridis GV. Risk factors for recurrence of primary sclerosing cholangitis after liver tranplantation. Liver Transpl, in press.
86. Graziadei I.W. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 8 (2002) 575-581
87. Vera A., Moledina S., Gunson B., et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 360 (2002) 1943-1944
88. Boker K.H., Dalley G., Bahr M.J., et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 25 (1997) 203-210
89. Burroughs A.K. Posttransplantation prevention and treatment of recurrent hepatitis C. Liver Transpl 6 (2000) S35-S40
90. Marzano A., Smedile A., Abate M., et al. Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. J Hepatol 21 (1994) 961-965
91. Wright T.L., Donegan E., Hsu H.H., et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 103 (1992) 317-322
92. Takahashi T., Ashizawa S., Matsumoto H., et al. Fibrosing cholestatic hepatitis developing after liver transplantation: case report of a patient with HCV-related cirrhosis. Transplant Proc 35 (2003) 392-393
93. Papatheodoridis G.V., Patch D., Dusheiko G.M., et al. The outcome of hepatitis C virus infection after liver transplantation: is it influenced by the type of immunosuppression?. J Hepatol 30 (1999) 731-738
94. Schluger L.K., Sheiner P.A., Thung S.N., et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 23 (1996) 971-976
95. Taga S.A., Washington M.K., Terrault N., et al. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg 4 (1998) 304-310
96. Deshpande V., Burd E., Aardema K.L., et al. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. Liver Transpl 7 (2001) 118-124
97. Roche B., and Samuel D. Aspects of hepatitis C virus infection relating to liver transplantation. Eur J Gastroenterol Hepatol 18 (2006) 313-320
98. Gaglio P.J., Malireddy S., Levitt B.S., et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 9 (2003) 1028-1035
99. Shiffman M.L., Stravitz R.T., Contos M.J., et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 10 (2004) 1248-1255
100. Aucejo F., Rofaiel G., and Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?. J Hepatol 44 (2006) 19-23
101. Dhillon M.S., Rai J.K., Gunson B.K., et al. Post-transplant lymphoproliferative disease in liver transplantation. Br J Radiol 80 (2007) 337-346
102. Kremers W.K., Devarbhavi H.C., Wiesner R.H., et al. Post-transplant lymphoproliferative disordersfollowing liver transplantation: incidence, risk factors and survival. Am J Transplant 6 (2006) 1017-1024
103. Ben-Ari Z., Amlot P., Lachmanan S.R., et al. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl Surg 5 (1999) 184-191
104. Timuragaoglu A., Ugur-Bilgin A., Colak D., et al. Posttransplant lymphoproliferative disorders in transplant recipients. Transplant Proc 38 (2006) 641-645
105. Jain A., Nalesnik M., Reyes J., et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 236 (2002) 429-436
106. Ghobrial I.M., Habermann T.M., Macon W.R., et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?. Transplantation 79 (2005) 244-247
107. Bakker N.A., van Imhoff G.W., Verschuuren E.A., et al. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 20 (2007) 207-218
108. Becker Y.T., Samaniego-Picota M., and Sollinger H.W. The emerging role of rituximab in organ transplantation. Transpl Int 19 (2006) 621-628
109. Aseni P., Vertemati M., Minola E., et al. Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. Liver Transpl 7 (2001) 816-823